OBJECTIVE: To examine the survival outcomes of septuagenarians and octogenarians (aged > or =80 years) who underwent radical prostatectomy (RP) at our institution, as the US Preventive Services Task Force recently released recommendations that men aged > or =75 years should not be screened for prostate cancer. PATIENTS AND METHODS: Our institutional RP database (1982-2008) was queried for men aged > or =70 years at the time of surgery to evaluate actuarial survival after RP; 386 aged 70-81 years (median 71) underwent RP. The median (range) follow-up was 6.5 (1-22) years. Clinicopathological characteristics and mortality data were evaluated; mortality data were gathered through Social Security Administration Death Index and causes of death were confirmed with the Center for Disease Control National Death Index information. Kaplan-Meier analysis was used to evaluate cause-specific survival. RESULTS: Ten patients (2.6%) had clinical stage T1a-b, 213 (55.3%) had T1c, and 143 (37.1%) had T2 prostate cancer. The median (range) preoperative prostate-specific antigen (PSA) level was 6.2 (0.2-49.9) ng/mL, and the biopsy and pathological Gleason sum was 6 (3-9) and 7 (4-9), respectively. Causes of death included prostate cancer (17), other malignancies (14), cardiovascular causes (14), neurological disease (four), pneumonia (two) and accident (one). The prostate cancer-specific survival rate was 97.6%, 94.0% and 90.2% at 5, 10 and 15 years after RP, respectively; the respective cardiovascular survival rate was 99.5%, 97.6% and 92.5%, and the overall survival rate was 93.1%, 82.5% and 68.9%, respectively. CONCLUSIONS: If appropriately selected, older men have excellent overall and prostate-cancer specific survival after RP. The benefits of surgery should be weighed against the increased risks of surgical and anaesthetic complications.
OBJECTIVE: To examine the survival outcomes of septuagenarians and octogenarians (aged > or =80 years) who underwent radical prostatectomy (RP) at our institution, as the US Preventive Services Task Force recently released recommendations that men aged > or =75 years should not be screened for prostate cancer. PATIENTS AND METHODS: Our institutional RP database (1982-2008) was queried for men aged > or =70 years at the time of surgery to evaluate actuarial survival after RP; 386 aged 70-81 years (median 71) underwent RP. The median (range) follow-up was 6.5 (1-22) years. Clinicopathological characteristics and mortality data were evaluated; mortality data were gathered through Social Security Administration Death Index and causes of death were confirmed with the Center for Disease Control National Death Index information. Kaplan-Meier analysis was used to evaluate cause-specific survival. RESULTS: Ten patients (2.6%) had clinical stage T1a-b, 213 (55.3%) had T1c, and 143 (37.1%) had T2 prostate cancer. The median (range) preoperative prostate-specific antigen (PSA) level was 6.2 (0.2-49.9) ng/mL, and the biopsy and pathological Gleason sum was 6 (3-9) and 7 (4-9), respectively. Causes of death included prostate cancer (17), other malignancies (14), cardiovascular causes (14), neurological disease (four), pneumonia (two) and accident (one). The prostate cancer-specific survival rate was 97.6%, 94.0% and 90.2% at 5, 10 and 15 years after RP, respectively; the respective cardiovascular survival rate was 99.5%, 97.6% and 92.5%, and the overall survival rate was 93.1%, 82.5% and 68.9%, respectively. CONCLUSIONS: If appropriately selected, older men have excellent overall and prostate-cancer specific survival after RP. The benefits of surgery should be weighed against the increased risks of surgical and anaesthetic complications.
Authors: S Ahmad; F O'Kelly; R P Manecksha; I M Cullen; R J Flynn; T E D McDermott; R Grainger; J A Thornhill Journal: Ir J Med Sci Date: 2011-09-11 Impact factor: 1.568
Authors: Jae Hyun Ryu; Yun Beom Kim; Tae Young Jung; Sun Il Kim; Seok-Soo Byun; Dong Deuk Kwon; Duk Yoon Kim; Tae Hee Oh; Tag Keun Yoo; Woo Jin Ko Journal: J Korean Med Sci Date: 2016-04-25 Impact factor: 2.153